NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.3 Sex hormones and hormone antagonists in malignant disease > 8.3.4 Hormone antagonists > 8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists > Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - NICE TAG TA316

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - NICE TAG TA316

1.1 Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic hormone‑relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy, only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.

1.2 The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.

http://www.nice.org.uk/guidance/TA316

Site by Devopa
© Copyright 2020 NHS. All rights reserved.